BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...$3M seed round for LucidLucid Scientific Inc. raised a $3 million seed round led by Dynamk Capital...
...Other) sotorasib (AMG 510) lifileucel (LN-144, contego, TILs) omburtamab, 124I-8H9 (B7-H3), burtomab (8h9) Eidos Therapeutics BridgeBio Pharma Hugo Biotech Zhejiang Taimei Medical Technology Dynamk Capital Lucid...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...He was CMO and chief development officer of AnaptysBio Inc. (NASDAQ:ANAB). Life sciences VC firm Dynamk Capital...
...Sawka, BioCentury Staff Emergent BioSolutions Inc. Arix Bioscience plc AlloVir Asklepios BioPharmaceutical Inc. Gritstone Oncology Inc. Calliditas Therapeutics AB Gadeta B.V. Seres Therapeutics Inc. Dynamk Capital Polyneuron...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...at $4.8 million, adding additional funds to the $3.6 million first tranche raised in January. Dynamk Capital...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...Inc. has raised $3.6 million in an initial seed financing co-led by Cota Capital and Dynamk Capital...
BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

...far raised at least $15 million as part of a series B round led by Dynamk Capital...
BioCentury | May 30, 2019
Company News

Management tracks: Sanofi hires Atara's Berger; plus Emmaus, enGene and more

...non-viral vector platform to deliver gene therapies via oral administration. Early stage life sciences investor Dynamk Capital...
...as a venture partner. Mahler was CEO of AGC Biologics A/S (Bothell, Wash.). Mark Zipkin, Staff Writer Dynamk Capital Emmaus...
BioCentury | Nov 16, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...what would typically take industry a year and a half. Daniella Kranjac, founding partner of Dynamk Capital...
...focused on incremental process improvements, but academics and entrepreneurs are pushing the envelope.” Daniella Kranjac, Dynamk Capital...
BioCentury | Nov 15, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...what would typically take industry a year and a half. Daniella Kranjac, founding partner of Dynamk Capital...
...focused on incremental process improvements, but academics and entrepreneurs are pushing the envelope.” Daniella Kranjac, Dynamk Capital...
BioCentury | Dec 8, 2017
Financial News

AI newco Envisagenics raises $2.4M in seed round

...$2.4 million in a seed round. Third Kind Venture Capital, Cosine LLC, Dolby Family Ventures, Dynamk Capital...
Items per page:
1 - 9 of 9
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...$3M seed round for LucidLucid Scientific Inc. raised a $3 million seed round led by Dynamk Capital...
...Other) sotorasib (AMG 510) lifileucel (LN-144, contego, TILs) omburtamab, 124I-8H9 (B7-H3), burtomab (8h9) Eidos Therapeutics BridgeBio Pharma Hugo Biotech Zhejiang Taimei Medical Technology Dynamk Capital Lucid...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...He was CMO and chief development officer of AnaptysBio Inc. (NASDAQ:ANAB). Life sciences VC firm Dynamk Capital...
...Sawka, BioCentury Staff Emergent BioSolutions Inc. Arix Bioscience plc AlloVir Asklepios BioPharmaceutical Inc. Gritstone Oncology Inc. Calliditas Therapeutics AB Gadeta B.V. Seres Therapeutics Inc. Dynamk Capital Polyneuron...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...at $4.8 million, adding additional funds to the $3.6 million first tranche raised in January. Dynamk Capital...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...Inc. has raised $3.6 million in an initial seed financing co-led by Cota Capital and Dynamk Capital...
BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

...far raised at least $15 million as part of a series B round led by Dynamk Capital...
BioCentury | May 30, 2019
Company News

Management tracks: Sanofi hires Atara's Berger; plus Emmaus, enGene and more

...non-viral vector platform to deliver gene therapies via oral administration. Early stage life sciences investor Dynamk Capital...
...as a venture partner. Mahler was CEO of AGC Biologics A/S (Bothell, Wash.). Mark Zipkin, Staff Writer Dynamk Capital Emmaus...
BioCentury | Nov 16, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...what would typically take industry a year and a half. Daniella Kranjac, founding partner of Dynamk Capital...
...focused on incremental process improvements, but academics and entrepreneurs are pushing the envelope.” Daniella Kranjac, Dynamk Capital...
BioCentury | Nov 15, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...what would typically take industry a year and a half. Daniella Kranjac, founding partner of Dynamk Capital...
...focused on incremental process improvements, but academics and entrepreneurs are pushing the envelope.” Daniella Kranjac, Dynamk Capital...
BioCentury | Dec 8, 2017
Financial News

AI newco Envisagenics raises $2.4M in seed round

...$2.4 million in a seed round. Third Kind Venture Capital, Cosine LLC, Dolby Family Ventures, Dynamk Capital...
Items per page:
1 - 9 of 9